# EDGAR Filing Document

**Accession Number:** 0001614744
**File Stem:** 0000000000-23-003229
**Filing Date:** 2023-3
**Character Count:** 2639
**Document Hash:** def151c98b7d5aad1e1fdabd5aeceba0
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-23-003229.hdr.sgml**: 20230503

**ACCESSION NUMBER**: 0000000000-23-003229

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20230330

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** PURPLE BIOTECH LTD.
- **CENTRAL INDEX KEY:** 0001614744
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** L3
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD

**BUSINESS ADDRESS:**
- **STREET 1:** 4 OPPENHEIMER STREET
- **STREET 2:** SCIENCE PARK
- **CITY:** REHOVOT
- **STATE:** L3
- **ZIP:** 7670104
- **BUSINESS PHONE:** 97239333121

**MAIL ADDRESS:**
- **STREET 1:** 4 OPPENHEIMER STREET
- **STREET 2:** SCIENCE PARK
- **CITY:** REHOVOT
- **STATE:** L3
- **ZIP:** 7670104

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Kitov Pharma Ltd.
- **DATE OF NAME CHANGE:** 20180125

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Kitov Pharmaceuticals Holdings Ltd.
- **DATE OF NAME CHANGE:** 20140724
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001213900-23-022248

## Text-Extract

```

United States securities and exchange commission logo

                          March 30, 2023

       Gil Efron
       Chief Executive Officer
       PURPLE BIOTECH LTD.
       4 Oppenheimer Street, Science Park
       Rehovot 7670104, Israel

                                                        Re: PURPLE BIOTECH LTD.
                                                            Registration
Statement on Form F-3
                                                            Filed March 23,
2023
                                                            File No. 333-270769

       Dear Gil Efron:

              This is to advise you that we have not reviewed and will not
review your registration
       statement.

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

                                                        Please contact Cindy
Polynice at 202-551-8707 with any questions.

                          Sincerely,

                          Division of Corporation Finance

                          Office of Life Sciences
       cc:                                              Jayun Koo, Esq.

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._